PL2118098T3 - Postacie polimorficzne makrocyklicznego inhibitora HCV - Google Patents

Postacie polimorficzne makrocyklicznego inhibitora HCV

Info

Publication number
PL2118098T3
PL2118098T3 PL08708575T PL08708575T PL2118098T3 PL 2118098 T3 PL2118098 T3 PL 2118098T3 PL 08708575 T PL08708575 T PL 08708575T PL 08708575 T PL08708575 T PL 08708575T PL 2118098 T3 PL2118098 T3 PL 2118098T3
Authority
PL
Poland
Prior art keywords
hcv
polymorphic forms
macrocyclic inhibitor
macrocyclic
inhibitor
Prior art date
Application number
PL08708575T
Other languages
English (en)
Inventor
Sigrid Carl Maria Stokbroekx
Carina Leys
Kelly Ann Swinney
Stijn Wuyts
Andras Horvath
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38229348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2118098(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of PL2118098T3 publication Critical patent/PL2118098T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL08708575T 2007-02-01 2008-02-01 Postacie polimorficzne makrocyklicznego inhibitora HCV PL2118098T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07101563 2007-02-01
PCT/EP2008/051268 WO2008092954A2 (en) 2007-02-01 2008-02-01 Polymorphic forms of a macrocyclic inhibitor of hcv
EP08708575.9A EP2118098B1 (en) 2007-02-01 2008-02-01 Polymorphic forms of a macrocyclic inhibitor of hcv

Publications (1)

Publication Number Publication Date
PL2118098T3 true PL2118098T3 (pl) 2015-03-31

Family

ID=38229348

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08708575T PL2118098T3 (pl) 2007-02-01 2008-02-01 Postacie polimorficzne makrocyklicznego inhibitora HCV

Country Status (25)

Country Link
US (1) US8143402B2 (pl)
EP (1) EP2118098B1 (pl)
JP (1) JP5523110B2 (pl)
KR (1) KR101580226B1 (pl)
CN (3) CN105037347B (pl)
AR (2) AR065136A1 (pl)
AU (1) AU2008209696B2 (pl)
BR (1) BRPI0806945A2 (pl)
CA (1) CA2677170C (pl)
CL (1) CL2008000321A1 (pl)
CY (1) CY1116339T1 (pl)
DK (1) DK2118098T3 (pl)
ES (1) ES2524784T3 (pl)
HK (1) HK1205125A1 (pl)
HR (1) HRP20141137T1 (pl)
IL (1) IL199215A (pl)
MX (1) MX2009008275A (pl)
NZ (1) NZ577568A (pl)
PL (1) PL2118098T3 (pl)
PT (1) PT2118098E (pl)
RU (1) RU2533830C2 (pl)
SI (1) SI2118098T1 (pl)
TW (1) TWI423968B (pl)
WO (1) WO2008092954A2 (pl)
ZA (1) ZA200905377B (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
SMT201700121T1 (it) * 2009-02-27 2017-03-08 Janssen Pharmaceuticals Inc Sale amorfo di un inibitore macrociclico di hcv
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
AR077712A1 (es) 2009-08-05 2011-09-14 Idenix Pharmaceuticals Inc Inhibidores de serina proteasa macrociclica
CA2788155C (en) 2010-01-27 2018-04-24 AB Pharma Ltd. Polyheterocyclic compounds highly potent as hcv inhibitors
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
CA2833887A1 (en) * 2011-05-04 2012-11-08 Merck Sharp & Dohme Corp. Drug substances, pharmaceutical compositions and methods for preparing the same
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8962810B2 (en) 2011-06-16 2015-02-24 AB Pharma Ltd. Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof
EP2755944B1 (en) 2011-09-16 2017-06-14 Sanofi Biarylderivatives,their preparation and their therapeutic application
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
JP6154474B2 (ja) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN104995189B (zh) * 2014-01-21 2017-03-29 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
CN105308043B (zh) * 2014-05-29 2018-01-30 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
CZ2015220A3 (cs) * 2015-03-27 2016-10-05 Zentiva, K.S. Amorfní sůl makrocyklického inhibitoru viru hepatitidy C
WO2016177625A1 (en) 2015-05-04 2016-11-10 Sandoz Ag Amorphous simeprevir potassium
CN105503851B (zh) * 2015-12-09 2017-06-23 重庆润生科技有限公司 一种烯基噻唑衍生物的制备方法
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1771050A (zh) * 2003-02-07 2006-05-10 益安药业 丙型肝炎丝氨酸蛋白酶的大环抑制剂
CN1894274A (zh) * 2003-09-26 2007-01-10 先灵公司 丙肝病毒ns3丝氨酸蛋白酶的大环抑制剂
WO2005037214A2 (en) * 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
ES2336009T3 (es) * 2004-01-30 2010-04-07 Medivir Ab Inhibidores de la ns-3 serina proteasa del vhc.
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c

Also Published As

Publication number Publication date
CN101589040A (zh) 2009-11-25
JP5523110B2 (ja) 2014-06-18
WO2008092954A3 (en) 2008-10-02
CA2677170C (en) 2017-04-18
TWI423968B (zh) 2014-01-21
CN105037347B (zh) 2018-06-01
AR108819A2 (es) 2018-09-26
US8143402B2 (en) 2012-03-27
RU2009132660A (ru) 2011-03-10
US20100029715A1 (en) 2010-02-04
WO2008092954A8 (en) 2009-12-23
AR065136A1 (es) 2009-05-20
IL199215A (en) 2015-10-29
DK2118098T3 (en) 2014-12-08
WO2008092954A2 (en) 2008-08-07
TW200846347A (en) 2008-12-01
PT2118098E (pt) 2014-12-09
KR20090115929A (ko) 2009-11-10
ZA200905377B (en) 2010-10-27
ES2524784T3 (es) 2014-12-12
NZ577568A (en) 2012-02-24
BRPI0806945A2 (pt) 2014-05-06
CN104230918A (zh) 2014-12-24
CA2677170A1 (en) 2008-08-07
KR101580226B1 (ko) 2015-12-24
EP2118098A2 (en) 2009-11-18
SI2118098T1 (sl) 2015-01-30
RU2533830C2 (ru) 2014-11-20
CY1116339T1 (el) 2017-02-08
HRP20141137T1 (hr) 2015-01-30
JP2010517971A (ja) 2010-05-27
EP2118098B1 (en) 2014-09-24
CN105037347A (zh) 2015-11-11
CN104230918B (zh) 2018-01-26
HK1137438A1 (en) 2010-07-30
AU2008209696A1 (en) 2008-08-07
CL2008000321A1 (es) 2008-08-22
AU2008209696B2 (en) 2013-05-09
HK1205125A1 (en) 2015-12-11
MX2009008275A (es) 2009-08-12

Similar Documents

Publication Publication Date Title
ZA200905377B (en) Polymorphic forms of a macrocyclic inhibitor of HCV
SI2121674T1 (sl) Postopki in intermediati za pripravo makrocikličnega proteaznega inhibitorja HCV
IL195029A0 (en) Polymorphs
IL210345A0 (en) Crystalline forms of a 2 - thiazolyl - 4 - quinolinyl - oxy derivative, a potent hcv inhibitor
PT2094708E (pt) Pirrolopirazina como inibidor da cinase syk
EP2036894A4 (en) AURORA INHIBITOR
EP1978966A4 (en) TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE
ZA200902496B (en) HCV Nucleoside Inhibitor
BRPI0807087A2 (pt) Inibidores de hcv macrocíclicos substituídos de pirimidina
IL195515A0 (en) Macrocyclic oximyl hepatitis c protease inhibitors
IL199640A0 (en) Hcv inhibiting macrocyclic phenylcarbamates
IL196706A0 (en) Crystalline forms of rapamycin analogs
IL243058A0 (en) Amorphous salt of macrocyclic hcv inhibitor
IL213246A0 (en) Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
ZA200903609B (en) Motilide polymorphs
GB201002676D0 (en) Inhibition of alpha synuclein toxicity
GB0623381D0 (en) Use of a compound as VEGF inhibitor
EP1983997A4 (en) CRYSTALLINE FORMS OF A FARNESYL DIBENZODIAZEPINONE
GB0619888D0 (en) New polymorphic forms of pregabalin
ZA200900740B (en) Crystalline forms of rapamycin analogs
GB0700807D0 (en) A method of printing
GB0617364D0 (en) Inflatable show junp
GB0700742D0 (en) A method of syndicating a property